Biogen Files 8-K on Financial Results, Operations
Ticker: BIIB · Form: 8-K · Filed: 2024-02-13T00:00:00.000Z
Sentiment: neutral
Topics: financial-results, operations, 8-K, corporate-filing
TL;DR
**Biogen just dropped an 8-K with fresh financial results, get ready for potential stock movement.**
AI Summary
Biogen Inc. filed an 8-K on February 13, 2024, to report its results of operations and financial condition. This filing, under the Securities Exchange Act of 1934, indicates that the company is providing updated financial information. For investors, this matters because it offers a timely look into Biogen's recent financial performance, which can influence stock valuation and future investment decisions.
Why It Matters
This filing provides investors with current financial information, crucial for assessing Biogen's health and making informed decisions about buying, holding, or selling its stock.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial results, which is standard for public companies and does not inherently present a high risk.
Analyst Insight
A smart investor would review the detailed financial statements and results that accompany this 8-K to understand Biogen's current performance and future outlook before making any investment decisions.
Key Players & Entities
- BIOGEN INC. (company) — the registrant filing the 8-K
- February 13, 2024 (date) — date of earliest event reported and filing date
- 0-19311 (other) — Commission File Number for Biogen Inc.
- BIIB (other) — trading symbol for Biogen Inc. Common Stock
- The Nasdaq Global Select Market (other) — exchange where Biogen Inc. Common Stock is registered
FAQ
What is the purpose of Biogen Inc.'s 8-K filing dated February 13, 2024?
The purpose of Biogen Inc.'s 8-K filing on February 13, 2024, is to report on its 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as per the 'ITEM INFORMATION' section of the filing.
What is Biogen Inc.'s trading symbol and on which exchange is its common stock registered?
Biogen Inc.'s trading symbol is BIIB, and its Common Stock, with a $0.0005 par value, is registered on The Nasdaq Global Select Market, as stated in the 'Title of each class' section of the filing.
What is the address of Biogen Inc.'s principal executive offices?
The address of Biogen Inc.'s principal executive offices is 225 Binney Street, Cambridge, Massachusetts 02142, according to the filing's business address information.
Under which Act is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934, as indicated in the 'CURRENT REPORT' section.
Has Biogen Inc. changed its name previously, and if so, what was a former name and when did it change?
Yes, Biogen Inc. has changed its name previously. One former name was BIOGEN IDEC INC., with a date of name change on April 27, 2007, as listed under 'FORMER COMPANY' data.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-02-13 07:07:23
Key Financial Figures
- $0.0005 — ange on which registered Common Stock, $0.0005 par value BIIB The Nasdaq Global Select
Filing Documents
- biib-20240213.htm (8-K) — 23KB
- exhibit991-q42023pressrele.htm (EX-99.1) — 574KB
- newbiogenlogo.jpg (GRAPHIC) — 3KB
- 0000875045-24-000004.txt ( ) — 764KB
- biib-20240213.xsd (EX-101.SCH) — 2KB
- biib-20240213_lab.xml (EX-101.LAB) — 24KB
- biib-20240213_pre.xml (EX-101.PRE) — 12KB
- biib-20240213_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 13, 2024, Biogen Inc. issued a press release announcing its results of operations and financial condition for the fourth quarter and year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The exhibits listed below are furnished as part of this Current Report on Form 8-K. Exhibit No. Description 99.1 Biogen's press release dated February 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOGEN INC. By: /s/ Wendell Taylor Wendell Taylor Secretary Date: February 13, 2024